Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer

被引:0
|
作者
Norie Abe
Hirofumi Matsumoto
Reika Takamatsu
Kentaro Tamaki
Naoko Takigami
Kano Uehara
Yoshihiko Kamada
Nobumitsu Tamaki
Tokiwa Motonari
Mikiko Unesoko
Norihiro Nakada
Hisamitsu Zaha
Naoki Yoshimi
机构
[1] Nakagami Hospital,Department of Breast Surgery
[2] University of the Ryukyus,Department of Pathology and Oncology, Graduate School of Medicine
[3] Ryukyu University Hospital,Department of Pathology
[4] Nahanishi Clinic,Department of Breast Surgical Oncology
[5] Nakagami Hospital,Department of Pathology
来源
Virchows Archiv | 2020年 / 476卷
关键词
Tumor-infiltrating lymphocyte (TIL); Image analysis; HER2; Pathological complete response (pCR);
D O I
暂无
中图分类号
学科分类号
摘要
As visual quantification of the density of tumor-infiltrating lymphocytes (TILs) lacks in precision, digital image analysis (DIA) approach has been applied in order to improve. In several studies, TIL density has been examined on hematoxylin and eosin (HE)-stained sections using DIA. The aim of the present study was to quantify TIL density on HE sections of core needle biopsies using DIA and investigate its association with clinicopathological parameters and pathological response to neoadjuvant chemotherapy in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The study cohort comprised of patients with HER2-positive breast cancer, all treated with neoadjuvant anti-HER2 therapy. DIA software applying machine learning-based classification of epithelial and stromal elements was used to count TILs. TIL density was determined as the number of TILs per square millimeter of stromal tissue. Median TIL density was 1287/mm2 (range, 123–8101/mm2). A high TIL density was associated with higher histological grade (P = 0.02), estrogen receptor negativity (P = 0.036), and pathological complete response (pCR) (P < 0.0001). In analyses using receiver operating characteristic curves, a threshold TIL density of 2420/mm2 best discriminated pCR from non-pCR. In multivariate analysis, high TIL density (> 2420/mm2) was significantly associated with pCR (P < 0.0001). Our results indicate that DIA can assess TIL density quantitatively, machine learning-based classification algorithm allowing determination of TIL density as the number of TILs per unit area, and TIL density established by this method appears to be an independent predictor of pCR in HER2-positive breast cancer.
引用
收藏
页码:701 / 709
页数:8
相关论文
共 50 条
  • [31] Prognostic associations of tumor-infiltrating lymphocytes (TIL) in metastatic HER2-positive breast cancer (BC) treated with trastuzumab and pertuzumab: A secondary analysis of the CLEOPATRA study
    Luen, S.
    Salgado, R.
    Stephen, F.
    Peter, S.
    Jennifer, E-W
    Emma, C.
    Astrid, K.
    Sandra, S. M.
    Jose, B.
    Stefan, M.
    Sherene, L.
    CANCER RESEARCH, 2017, 77
  • [32] Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
    Yang, Xia
    Rao, Jia
    Yang, Wentao
    Shui, Ruohong
    TARGETED ONCOLOGY, 2018, 13 (06) : 757 - 767
  • [33] Tumor infiltrating lymphocytes as a predictive factor in Pertuzumab/Trastuzumab-treated HER2-positive breast cancer
    Saito, Kanako
    Kotsuka, Yuji
    Oda, Hiroyasu
    Ishihara, Mikiya
    Tamaru, Satoshi
    Yamashita, Yoshiki
    Mizuno, Toshiro
    Katayama, Naoyuki
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
    Xia Yang
    Jia Rao
    Wentao Yang
    Ruohong Shui
    Targeted Oncology, 2018, 13 : 757 - 767
  • [35] Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer
    Chaohui Lisa Zhao
    Kamaljeet Singh
    Alexander S. Brodsky
    Shaolei Lu
    Theresa A. Graves
    Mary Anne Fenton
    Dongfang Yang
    Ashlee Sturtevant
    Murray B. Resnick
    Yihong Wang
    BMC Cancer, 19
  • [36] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Vialel, G.
    Curigliano, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 347 - 354
  • [37] Tumor infiltrating lymphocytes and hydrophobic amino acid changes in HER2-positive metastatic breast cancer.
    Kotoula, Vassiliki
    Giannoulatou, Eleni
    Alexopoulou, Zoi
    Karavasilis, Vasilios
    Kotsakis, Athanasios
    Dionysopoulos, Dimitrios
    Christodoulou, Christos
    Tsolaki, Eleftheria
    Bobos, Mattheos
    Charalambous, Elpida
    Pentheroudakis, George E.
    Makatsoris, Thomas
    Chrisafi, Sofia
    Pectasides, Dimitrios G.
    Psyrri, Amanda
    Papakostas, Pavlos
    Razis, Evangelia
    Bafaloukos, Dimitris
    Georgoulias, Vasileios
    Fountzilas, George
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer
    C. Criscitiello
    A. Vingiani
    P. Maisonneuve
    G. Viale
    G. Viale
    G. Curigliano
    Breast Cancer Research and Treatment, 2020, 183 : 347 - 354
  • [39] Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer
    Zhao, Chaohui Lisa
    Singh, Kamaljeet
    Brodsky, Alexander S.
    Lu, Shaolei
    Graves, Theresa A.
    Fenton, Mary Anne
    Yang, Dongfang
    Sturtevant, Ashlee
    Resnick, Murray B.
    Wang, Yihong
    BMC CANCER, 2019, 19 (01)
  • [40] Stromal ColXα1 and Tumor-Infiltrating Lymphocytes Predict Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer Depending on Estrogen Receptor Status
    Ouseph, Madhu
    Brodsky, Alexander
    Xiong, Jinjun
    Yang, Dongfang
    Resnick, Murray B.
    Wang, Yihong
    LABORATORY INVESTIGATION, 2016, 96 : 63A - 63A